Patents Examined by Paul C. Martin
  • Patent number: 11639941
    Abstract: The present invention includes a method and apparatus for measuring the transport of analytes from living, biological cells through a cell barrier, which includes, but is not limited to, steps of providing the living, biological cells loaded with analytes, unloading at least a portion of said analytes from the cells through ion channels, removing unloaded analyte remaining in the cells, and measuring the analytes using x-ray fluorescence, specifically wherein the measurement uses an energy dispersive x-ray fluorescence spectrometer equipped with a microfocus x-ray tube. These steps may be repeated so that multiple measurements can be obtained over a period of time.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: May 2, 2023
    Assignee: Icagen, LLC
    Inventors: Benjamin P. Warner, Lori J. Peterson, Jennifer A. Berger, Eva R. Birnbaum, Rebecca L. E. Miller
  • Patent number: 11618861
    Abstract: This disclosure describes processes for using a single cellulosic feedstock or a combination of two or more different cellulosic feedstocks with a starch component to produce a fermented product. The process includes separating the components of the cellulosic feedstocks with fractionation, pretreating a component with wet fractionation with chemicals, hydrolysis and fermentation of the pretreated feedstock(s) to produce cellulosic biofuel. The process may include combining the cellulosic feedstock(s) with other components to a cook and/or a fermentation process, distilling and dehydrating the combined components to produce the bio fuel. The process may also include producing a whole stillage stream from the feedstock(s) and mechanically processing the whole stillage stream to produce a high-value protein animal feed.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: April 4, 2023
    Assignee: ICM, Inc.
    Inventors: Jeremy Edward Javers, Christopher Riley William Gerken, Charles C. Gallop, Samuel Vander Griend, Jesse Spooner, Jonathon Phillip Licklider, Laercio Malburg, Ryan Edward Hoefling, Douglas Bernard Rivers, Kurt A. Dieker
  • Patent number: 11612630
    Abstract: A biochemical scaffold for regulating mammalian cell function. The biochemical scaffold includes a base liquid medium, a bioenergetic platform and a vibrational platform. The bioenergetic platform includes at least one Krebs cycle modulator and the vibrational platform includes at least one energy signature component, e.g., an herb. The biochemical scaffold is subjected to sequential harmonic oscillation at defined frequency ranges for a defined, predetermined period of time, wherein the energy signature of the energy signature component is imparted to, captured, replicated, and retained by liquid medium, and, when the biochemical scaffold is delivered to and, thus, in communication with biological tissue, the biochemical scaffold induces specific biochemical activities via the resonant transfer of the retained energy signature to the biological tissue and, hence, endogenous cells thereof, the biochemical activities including increased bioavailability of ATP.
    Type: Grant
    Filed: October 7, 2022
    Date of Patent: March 28, 2023
    Assignee: Next2Me, LLC
    Inventors: Ralph L Peterson, Renee D Williman
  • Patent number: 11613743
    Abstract: The present invention claims a novel process for the production and purification of microbial collagenase (Microbial Collagenase EC 3.4.24.3) produced by the non-pathogenic aerobic bacterium Vibrio alginolyticus chemovar. iophagus (NCIMB Number: 11038, synonym LMG 3418, hereinafter called Vibrio alginolyticus), which said process provides high production levels of collagenase with a stable, reproducible, cheap fermentation process. The collagenase produced from Vibrio alginolyticus according to the process described herein also presents a specific activity superior to that of other microbial collagenases, is stable in aqueous solution, and can be frozen without significant damage.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: March 28, 2023
    Assignee: FIDIA FARMACEUTICI S.p.A.
    Inventors: Susanna Vaccaro, Michele Caputo, Christian Cuppari, Giovanni Gennari
  • Patent number: 11592453
    Abstract: Disclosed herein is a method of providing a metabololipidomic profile and SPM signature on the progress of the innate host defense response following blood clotting. The method can include the step of taking one or more measurements in a patient's blood sample, wherein the sample is obtained during the time-course of clotting or coagulation or following clotting or coagulation, of pro-thrombotic and pro-inflammatory mediators (eicosanoids) and specialized pro-resolving mediators SPMs. From these measurements, a personalized metabololipidomic profile can be obtained. By comparing the measurement to that taken from normal or reference blood, a comparison profile can be developed. The profile comparison profile can then be used to make a medical or therapeutic decision.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: February 28, 2023
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Charles N. Serhan, Nan Chiang, Paul Norris
  • Patent number: 11584946
    Abstract: The present disclosure relates to testing, analysis and treatment of an environment, wherein one or more baseline(s) is established for the environment. Systems and methods for detecting, treating, comparing and testing for mold, mold spores and mold fragments physically present or in the air of an environment are disclosed herein, as well as methods for remediating the effects of mold in the environment.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: February 21, 2023
    Inventor: Gregory M. Gandee
  • Patent number: 11547301
    Abstract: The present disclosure relates to methods of collecting and testing bacteria containing samples from within the gastrointestinal (GI) tract of a subject. The methods may include disposing an ingestible device in the GI tract, collecting a bacteria-containing sample from the GI tract, selectively lysing eukaryotic cells in the sample by combining the sample with a dried reagent, exposing bacteria in the sample to resazurin in the ingestible device to produce resorufin, emitting light from the ingestible device, the emitted light being filtered through an optical filter to control for scatter so that the light interacts with the resorufin to produce fluorescence, and measuring a total fluorescence from the resorufin; or a rate of change of fluorescence from the resorufin as a function of time within the GI tract of the subject; and correlating the measured parameter to a number of viable bacterial cells in the sample.
    Type: Grant
    Filed: March 10, 2021
    Date of Patent: January 10, 2023
    Assignee: Biora Therapeutics, Inc.
    Inventors: Sharat Singh, Mitchell Lawrence Jones, Christopher Loren Wahl
  • Patent number: 11541100
    Abstract: The present invention relates to a nanoperforator having a lipid-bilayer nanodisc and a membrane-structured protein surrounding the nanodisc and to a pharmaceutical composition having the nanoperforator as an active ingredient for preventing or treating viral infectious diseases. The use of the lipid-bilayer nanoperforator provided in the present invention can lead to the safe prevention or treatment of a disease caused by viral infection regardless of whether the virus is a variant or not, and thus the present invention can be widely used for the safe and effective treatment of viral infectious diseases.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: January 3, 2023
    Assignee: MVRIX CO., LTD.
    Inventors: Dae-Hyuk Kweon, Byoungjae Kong, Woo-Jae Chung, Baik Lin Seong, Sukchan Lee
  • Patent number: 11529383
    Abstract: A method for modulating cellular activity in a subject, consisting essentially of the steps: (i) forming a liquid composition, (ii) subjecting the liquid composition to sequential harmonic oscillation to provide a liquid biochemical scaffold and, (iii) delivering a therapeutically effective amount of said liquid biochemical scaffold to said subject.
    Type: Grant
    Filed: April 29, 2022
    Date of Patent: December 20, 2022
    Assignee: Next2Me, LLC
    Inventors: Ralph L Peterson, Renee D Williman
  • Patent number: 11512286
    Abstract: The invention relates to methods for generating multipotent mammary stem cells from isolated and cultured human breast luminal cells. The method comprises the steps: 1. isolating and growing normal differentiated cells in vitro; 2. treating the differentiated cells with either a conditioned medium from active fibroblasts or cytokine. The invention also relates to multipotent mammary stem cells, cultures of the multipotent stem cells, differentiated cells, tissues, organs derived from the culture multipotent stem cells isolated by the methods disclosed and therapeutic and other uses for those cells thereof.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: November 29, 2022
    Assignee: KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE
    Inventors: Abdelilah Aboussekhra, Huda H. Al-Khalaf, Hazem Ghebeh
  • Patent number: 11426680
    Abstract: The present invention relates generally to a method of reducing the level of at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) in a solution comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and von Willebrand factor (VWF), the method comprising: (i) passing a feedstock comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF through a hydrophobic charge-induction chromatographic resin under conditions selected such that at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) present in the feedstock is bound to the resin; and (ii) recovering a solution comprising the at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF which passes through the resin, wherein the concentration of the at least one protein selected from the group consisting of pl
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: August 30, 2022
    Assignee: CSL BEHRING GmbH
    Inventors: Hung Pham, Jeffrey Michael Hey, Darren Nguy
  • Patent number: 11414645
    Abstract: The present invention relates to a cell culture support comprising a substrate and a polymeric blend layer bound to the substrate. The polymeric blend layer comprises at least one thermoresponsive polymer and at least one coupling agent. The coupling agent is a non-protein coupling agent that has functional thiol, ester, epoxy, or aldehyde groups. The cell culture support further includes cells supported by the polymeric blend layer, wherein the thermoresponsive polymer provides for temperature induced detachment of the cells and/or cell sheets.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: August 16, 2022
    Assignee: The University of Akron
    Inventors: Abdullah Alghunaim, Bi-min Zhang Newby
  • Patent number: 11352656
    Abstract: The present invention is related to compositions comprising clarified limulus amebocyte lysate (LAL), wherein the LAL is substantially free of coagulogen and methods of making such compositions. The invention further relates to a method of detecting an endotoxin in a sample using a chromogenic assay, the method comprising: (a) contacting the sample with a reagent comprising clarified LAL and a chromogenic substrate; and (b) measuring a chromogenic effect resulting from a change in the chromogenic substrate in the presence of endotoxin in the sample, wherein the LAL is substantially free of coagulogen. The invention also relates to kits comprising clarified LAL substantially free of coagulogen, and methods of making such.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: June 7, 2022
    Inventors: Candice Stumbaugh, Leben Tadesse, Karen Lin
  • Patent number: 11319342
    Abstract: Embodiments of the invention relate generally to protein extraction and, more generally, to bone protein extraction methods that do not require demineralization. In one embodiment, the invention provides a method comprising: mixing a bone sample and a quantity of an extraction buffer comprising: ammonium phosphate dibasic; or ammonium phosphate dibasic and ammonium bicarbonate; or ammonium phosphate dibasic, ammonium bicarbonate, and guanidine HCl; or sodium phosphate dibasic and sodium bicarbonate; or sodium phosphate dibasic, sodium bicarbonate, and guanidine HCl; or potassium phosphate dibasic and potassium bicarbonate; or potassium phosphate dibasic, potassium bicarbonate, and guanidine HCl; and incubating the bone sample/extraction buffer mixture.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: May 3, 2022
    Assignee: Rensselaer Polytechnic Institute
    Inventors: Timothy Paul Cleland, Deepak Vashishth
  • Patent number: 11318225
    Abstract: Thin parylene C membranes having smooth front sides and ultrathin regions (e.g., 0.01 ?m to 5 ?m thick) interspersed with thicker regions are disclosed. The back sides of the membranes can be rough compared with the smooth front sides. The membranes can be used in vitro to grow monolayers of cells in a laboratory or in vivo as surgically implantable growth layers, such as to replace the Bruch's membrane in the eye. The thin regions of parylene are semipermeable to allow for proteins in serum to pass through, and the thick regions give mechanical support for handling by a surgeon. The smooth front side allows for monolayer cell growth, and the rough back side helps prevents cells from attaching there.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: May 3, 2022
    Assignees: California Institute of Technology, University of Southern California
    Inventors: Yu-Chong Tai, Bo Lu, Mark Humayun
  • Patent number: 11291403
    Abstract: The present disclosure provides methods for determining an etiology of upper and/or lower eyelid puffiness by examining a subject with squinted eyes; and determining if upper and/or lower eyelid puffiness does not improve, improves, partially improves, or worsens, wherein the etiology of the upper and/or lower eyelid puffiness is diagnosed to be anterior to the orbicularis oculi muscle if the puffiness does not improve, wherein the etiology of the upper and/or lower eyelid puffiness is determined to be posterior to the orbicularis oculi muscle if the puffiness improves, wherein the etiology of the upper and/or lower eyelid puffiness is determined to be anterior and posterior to the orbicularis oculi muscle if the puffiness partially improves, or wherein the puffiness is determined to be secondary to hypertrophy of the orbicularis muscle or if the puffiness worsens.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: April 5, 2022
    Assignee: STANDARD OF CARE CORPORATION
    Inventors: Iliana E. Sweis, Bryan C. Cressey
  • Patent number: 11285100
    Abstract: The present application relates to a freeze-dried polymer composition containing chitosan and at least one lyoprotectant, a process for preparing a freeze-dried composition containing chitosan and at least one lyoprotectant and the use of a reconstituted freeze-dried chitosan composition to prepare implants for tissue repair.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: March 29, 2022
    Assignee: Ortho Regenerative Technologies Inc.
    Inventors: Anik Chevrier, Michael D. Buschmann, Daniel Veilleux, Caroline Hoemann, Marc Lavertu
  • Patent number: 11286448
    Abstract: An enzymatic processing plant for continuous flow-based enzymatic processing of organic molecules. The enzymatic processing plant including an enzymatic processing area, wherein the enzymatic processing area includes a turbulence-generating pipe with a repeatedly changing centre-line and/or a repeatedly changing cross-section, for generating turbulence to mix a reaction mixture and prevent sedimentation of particles as the reaction mixture is flowing through the turbulence-generating pipe. The enzymatic processing plant and the enzymatic processing area are arranged such that the reaction mixture is subjected to turbulence within the enzymatic processing area for a reaction time of 15 minutes or more.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: March 29, 2022
    Assignee: ALKYMAR AS
    Inventors: Olav Asle Djupevåg, Torstein Frantzen
  • Patent number: 11285179
    Abstract: The invention surprisingly found that Lactobacillus plantarum subsp. plantarum PS128 provides an advantageous effect in treatment or prevention of tic disorders and basal ganglia disorders. Accordingly, the invention provides a method of treating or preventing a movement disorder in a subject, comprising administering to a subject an effective amount of cells of a Lactobacillus plantarum subsp. plantarum PS128, which is deposited under DSMZ Accession No. DSM 28632.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: March 29, 2022
    Assignees: BENED BIOMEDICAL CO., LTD., ASIAN PROBIOTICS AND PREBIOTICS CORPORATION
    Inventors: Ying-Chieh Tsai, Chih-Chieh Hsu, Jian-Fu Liao, Yun-Fang Cheng, Shu-Ting You
  • Patent number: 11225636
    Abstract: The present invention relates to a method and system for aseptic material transfer from a storage container to a bioreactor. More precisely the invention relates to a method and system for aseptically transferring dry material, such as microcarriers for cell cultivation, to a bioreactor, comprising transferring microcarriers from a first container housing said microcarriers to a bioreactor for cell cultivation via r transfer tubing connecting the first container to the bioreactor, wherein the transfer is accomplished with pressurized air or gas supplied to the container.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: January 18, 2022
    Assignee: Cytiva Sweden AB
    Inventors: Bjorn Johan Lundgren, Emmanuel Macedo, Ann-Christin Magnusson, Lena Maria Sandberg